BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 20336387)

  • 1. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
    Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Hata S; Sakamoto Y; Yamamoto Y; Nara S; Esaki M; Shimada K; Kosuge T
    Ann Surg Oncol; 2012 Feb; 19(2):636-41. PubMed ID: 21863360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
    Waraya M; Yamashita K; Katagiri H; Ishii K; Takahashi Y; Furuta K; Watanabe M
    Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K; Iwaki K; Kai S; Ohta M; Kitano S
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
    Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
    Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Factors influencing survival of patients with cancer of the pancreatic head after resection].
    Gao CT; Li HK; Li Q
    Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):554-7. PubMed ID: 19950708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines.
    Motoi F; Rikiyama T; Katayose Y; Egawa S; Unno M
    Ann Surg Oncol; 2011 Feb; 18(2):371-9. PubMed ID: 20842460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.
    Hallemeier CL; Botros M; Corsini MM; Haddock MG; Gunderson LL; Miller RC
    Am J Clin Oncol; 2011 Dec; 34(6):567-72. PubMed ID: 21150564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exocrine-endocrine pancreatic cancer and alpha-fetoprotein.
    Brandi G; Nobili E; Capizzi E; Corti B; Di Cicilia R; Di Marco M; Biasco G
    Pancreas; 2008 Aug; 37(2):223-5. PubMed ID: 18665089
    [No Abstract]   [Full Text] [Related]  

  • 17. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
    Brown EG; Canter RJ; Bold RJ
    J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9.
    Lundin J; Roberts PJ; Kuusela P; Haglund C
    Anticancer Res; 1995; 15(5B):2181-6. PubMed ID: 8572621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
    Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
    World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.
    Malaguarnera M; Cristaldi E; Cammalleri L; Colonna V; Lipari H; Capici A; Cavallaro A; Beretta M; Alessandria I; Luca S; Motta M
    Arch Gerontol Geriatr; 2009; 48(2):213-7. PubMed ID: 18329114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.